Search

Exelixis Inc

Закрыт

СекторЗдравоохранение

66.01 -0.41

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

64.91

Макс.

67.31

Ключевые показатели

By Trading Economics

Доход

1.6M

212M

Продажи

18M

629M

P/E

Средняя по отрасли

20.539

50.373

Прибыль на акцию

0.82

Рентабельность продаж

33.729

Сотрудники

1,077

EBITDA

-5M

270M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

-19.35% downside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

2.3B

16B

Предыдущая цена открытия

66.42

Предыдущая цена закрытия

66.01

Exelixis Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

29 окт. 2026 г., 23:16 UTC

News

Exelixis reports Q3 2026 revenues of $658.7 million and GAAP net income of $218.1 million, exceeding analyst expectations, while shares declined in after-market trading.

28 окт. 2026 г., 22:01 UTC

Exelixis Inc saw a notable rise in after-market trading, continuing its upward trend after four consecutive sessions of higher closes.

27 окт. 2026 г., 19:36 UTC

Exelixis Inc is trading slightly higher, maintaining its position above the 20-day moving average and near the upper end of its one-month trading range.

26 окт. 2026 г., 20:07 UTC

News

Exelixis Inc shares are advancing amid a broader market rally, supported by positive economic indicators including the Dallas Fed Manufacturing Index exceeding expectations.

23 окт. 2026 г., 20:07 UTC

Exelixis Inc shares are declining amid a broadly lower market, reflecting rising oil prices, inflation concerns, and geopolitical tensions affecting investor sentiment.

21 окт. 2026 г., 19:26 UTC

Exelixis Inc shares are trading slightly higher, supported by positive momentum in the broader biotechnology sector, despite an earlier pullback from a session high.

20 окт. 2026 г., 20:08 UTC

Exelixis Inc shares advanced, closing significantly higher and reaching a notable peak, remaining well above its 20-day moving average.

19 окт. 2026 г., 20:07 UTC

News

Citizens maintains Market Outperform rating on Exelixis and raises price target to $65, contributing to a modest gain in the stock.

16 окт. 2026 г., 19:16 UTC

Exelixis Inc shares fell significantly from an early high, remaining above the 20-day moving average despite today's notable decline.

15 окт. 2026 г., 20:07 UTC

Exelixis Inc shares advanced, continuing a trend of gains since Wednesday's close, remaining significantly above its 20-day moving average despite an earlier pullback.

14 окт. 2026 г., 19:16 UTC

Exelixis Inc shares are advancing, reaching a notable peak in early afternoon trading and positioned well above its 20-day moving average.

13 окт. 2026 г., 20:08 UTC

Exelixis Inc shares are modestly lower, retracing from an early gain, amid a broader market decline.

12 окт. 2026 г., 21:02 UTC

Exelixis Inc shares declined in after-market trading, continuing lower since Monday's close and diverging from a recent trend of higher daily closes.

9 окт. 2026 г., 20:06 UTC

News

RBC Capital raised its price target on Exelixis Inc to $51 while maintaining a Sector Perform rating, coinciding with the stock's positive performance.

8 окт. 2026 г., 20:07 UTC

Exelixis Inc's shares advanced, supported by broader market strength, maintaining an upward trajectory despite an earlier pullback from a session high.

7 окт. 2026 г., 19:45 UTC

News

Exelixis Inc shares are trading higher as Truist Securities raises the price target to $54.00 from $52.00 while maintaining a Hold rating.

6 окт. 2026 г., 21:01 UTC

Exelixis Inc is trading modestly lower in after-market hours, positioned around the midpoint of its one-month trading range.

5 окт. 2026 г., 21:10 UTC

Exelixis Inc. is advancing in after-market trading, closing at its highest point of the day after three consecutive sessions of gains.

2 окт. 2026 г., 20:00 UTC

Exelixis Inc shares are advancing, reaching a peak cumulative return and remaining well above their 20-day moving average during Friday's market session.

1 окт. 2026 г., 20:07 UTC

Exelixis Inc's shares fell modestly, reflecting routine performance amid broader market conditions, and are currently near the low end of their daily range.

30 сент. 2026 г., 23:20 UTC

Exelixis Inc shares are higher in after-market trading, continuing a five-day gain, supported by strong Q2 GDP growth despite mixed inflation and consumer spending signals.

29 сент. 2026 г., 20:31 UTC

Exelixis Inc saw a significant decline in after-market trading, continuing a downward trend since Tuesday's close following earlier gains.

28 сент. 2026 г., 19:16 UTC

Exelixis Inc is trading modestly higher, currently 2.25% above its 20-day moving average, reflecting routine activity for this time of day.

25 сент. 2026 г., 23:20 UTC

Exelixis Inc is lower in after-market trading, retracing from an early gain and reflecting a decline since Friday's close.

24 сент. 2026 г., 20:01 UTC

Exelixis Inc is advancing, peaking in mid-afternoon while remaining above its 20-day moving average and near the upper end of its one-month range.

23 сент. 2026 г., 20:07 UTC

Exelixis Inc shares fell significantly on Wednesday, having briefly spiked earlier in the session, reflecting a lack of momentum in either direction.

22 сент. 2026 г., 20:06 UTC

Exelixis Inc is gaining today, building on Monday's momentum, with the stock remaining above its 20-day moving average and near its one-month range's upper end.

21 сент. 2026 г., 23:25 UTC

Exelixis Inc is trading modestly lower in after-market hours, continuing a decline seen over the past three sessions after reaching a session high.

18 сент. 2026 г., 20:06 UTC

Exelixis Inc's shares fell sharply after reaching a notable peak earlier in the session, while remaining above the 20-day moving average.

16 сент. 2026 г., 20:07 UTC

Exelixis Inc shares fell sharply, retracing from an early peak in cumulative return amid unusually high market volume on Wednesday.

Сравнение c конкурентами

Изменение цены

Exelixis Inc Прогноз

Целевая цена

By TipRanks

-19.35% падение

Прогноз на 12 месяцев

Средняя 53.455 USD  -19.35%

Максимум 65 USD

Минимум 41 USD

Основано на мнении 14 аналитиков Wall Street, спрогнозировавших целевые цены для Exelixis Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

14 ratings

4

Покупка

9

Удержание

1

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
help-icon Live chat